Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.57 Million ≈ $1.69 Million USD) by net assets (CN¥2.26 Billion ≈ $330.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Hubei Biocause Heilen Pharmaceutical Co. carry for a breakdown of total debt and financial obligations.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
0.046x |
|
Hippo Holdings Inc
NYSE:HIPO
|
0.040x |
|
Braskem S.A.
SA:BRKM3
|
0.215x |
|
W olf Photoelectric Technology Ltd
SHE:002962
|
0.015x |
|
Lg Electronics Pref
KO:066575
|
0.061x |
|
Kronos Worldwide Inc
NYSE:KRO
|
-0.010x |
|
Tatwah Smartech Co Ltd
SHE:002512
|
0.071x |
|
AFYA LTD. CL.A DL-00005
F:1AY
|
0.052x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Heilen Pharmaceutical Co. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.31 Billion ≈ $337.98 Million |
CN¥96.07 Million ≈ $14.06 Million |
0.042x | -28.48% |
| 2023-12-31 | CN¥2.36 Billion ≈ $344.86 Million |
CN¥137.06 Million ≈ $20.06 Million |
0.058x | -47.21% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.12 Million |
CN¥250.79 Million ≈ $36.70 Million |
0.110x | +97.51% |
| 2021-12-31 | CN¥2.22 Billion ≈ $325.26 Million |
CN¥123.98 Million ≈ $18.14 Million |
0.056x | -67.89% |
| 2020-12-31 | CN¥700.39 Million ≈ $102.49 Million |
CN¥121.67 Million ≈ $17.80 Million |
0.174x | -77.22% |
| 2019-12-31 | CN¥488.25 Million ≈ $71.45 Million |
CN¥372.33 Million ≈ $54.48 Million |
0.763x | +300.27% |
| 2018-12-31 | CN¥399.87 Million ≈ $58.51 Million |
CN¥76.18 Million ≈ $11.15 Million |
0.191x | +189.57% |
| 2017-12-31 | CN¥307.65 Million ≈ $45.02 Million |
CN¥-65.44 Million ≈ $-9.58 Million |
-0.213x | -- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more